3D Bioprinting in Medical Market Expected to Reach $4.9 Billion by 2032—Allied Market Research

According to a new report published by Allied Market Research, titled, “3D Bioprinting in Medical Market," The 3d bioprinting in medical market was valued at $1.1 billion in 2022, and is estimated to reach $4.9 billion by 2032, growing at a CAGR of 15.5% from 2023 to 2032.

3D bioprinting is a cutting-edge technique that involves the additive manufacturing of biomedical structures utilizing living cells, biological molecules, and biomaterials. In essence, it entails the layer-by-layer deposition of biological materials to construct 3D structures, mimicking tissues and organs. This innovative approach holds the potential to revolutionize regenerative medicine and healthcare by precisely creating complex biological constructs for various applications.  

The 3D bioprinting in medical market is driven by a rise in the number of people suffering from chronic diseases, heavy investments in R&D activities for tissue engineering, and technological advancements in 3D bioprinting technology contribute towards the market growth and are also the 3D bioprinting in medical market trends. For instance, CELLINK, a leading bioprinting company, offers the BIO X bioprinter, which exemplifies several technological advancements. BIO X is a versatile bioprinting platform that allows researchers to print multiple materials and cell types simultaneously. 

It features high precision and user-friendly software for designing complex structures. Moreover, it supports the integration of vascularization within printed tissues, addressing the challenge of creating vascular networks for enhanced functionality.  Furthermore, collaborative efforts between academic institutions, research organizations, and biotechnology companies contribute to the advancement of 3D bioprinting which also boosts 3D bioprinting in healthcare market. For instance, in November 2022, CollPlant, Tel Aviv University and Sheba Medical Center announced entering into a license and research agreement to co-develop rhCollagen-based 3D bioprinted human intestine model for drug discovery and personalized treatment of ulcerative colitis, thus boosting 3D bioprinting in healthcare market.

However, the high cost associated with 3D bioprinters, and dearth of skilled professionals are the key factors responsible for hampering the market growth. On the other hand, the rise in demand for 3D bioprinting in medical applications provides a lucrative opportunity for market growth. For instance, in September 2022, 3D Systems announced the formation of a new, wholly owned company called Systemic Bio, a biotech company focused on the application of advanced bioprinting technologies to pharmaceutical drug discovery and development.  

Depending on the products and solutions, the 3D bioprinting in medical market analysis is segmented into bioprinters, consumables & accessories, and software & services. The consumables & accessories segment dominated the 3D bioprinting in medical market share in 2022, owing to an increase in adoption of consumables & accessories for 3D bioprinting, ongoing innovation in materials, collaborative research efforts and rise in utilization of 3D bioprinting technology. However, the bioprinters segment is anticipated to register the highest CAGR during the forecast period, owing to rise in demand for 3D bioprinting across research, healthcare, and pharmaceutical industries propelled the demand for advanced bioprinter instruments. 

Depending on technology, the market is classified into extrusion based bioprinting, inkjet based bioprinting, laser assisted bioprinting, and others. The inkjet based bioprinting segment dominated the 3D bioprinting in medical market share in 2022 and is also expected to register the highest CAGR during the forecast period, owing to high adoption of the inkjet based bioprinting, precise & controlled method for depositing bioink, and high speed of inkjet-based bioprinting. Depending on application, the market is classified into tissue engineering & regenerative medicine, drug discovery & development, and others.  

The tissue engineering & regenerative medicine segment dominated the 3D bioprinting in medical market size in 2022 and is also expected to register the highest CAGR during the forecast period, owing to the increase in demand for personalized medicine and the need for reliable in vitro models for drug testing have further propelled the adoption of 3D cell culture techniques.  

Depending on the end user, the market is classified into biotechnology & pharmaceutical companies, academic & research institutes, and others. The academic & research institutes segment dominated the 3D bioprinting in medical market size in 2022 and is also expected to register the highest CAGR during the forecast period. This is attributed to continuously exploring new applications such as tissue engineering within the field of 3D bioprinting and rise in collaborative efforts with industry partners.  

Region wise, North America was the largest shareholder in the global 3D bioprinting in medical market in 2022 owing to easy availability of products for 3D bioprinting, widespread adoption of 3D printing technology, numerous collaborations between academic and commercial organizations, and well-developed healthcare infrastructure. In addition, the strong presence of key players and the rise in adoption of key strategies such as agreement and partnerships drive the 3D bioprinting in medical market forecast.

For instance, in October 2023, CELLINK, a leading global provider of bioprinting technologies, and the University of California, San Diego (UCSD), a world-renowned research institution, are pleased to announce their partnership to establish a 3D bioprinting Centre of Excellence.  However, Asia-Pacific is anticipated to register the highest CAGR during the forecast period owing to funding received by various start-up companies to introduce advanced 3D bioprinters, growing R&D activities, and an increasing focus on advanced medical technologies and increased healthcare expenditure. 

Key findings of the study   

• By products & solutions, the consumables & accessories segment was largest contributor to the 3D bioprinting in medical industry in 2022.    
• By technology, the inkjet based bioprinting segment was largest contributor to the market in 2022.    
• By application, the tissue engineering & regenerative medicine segment was largest contributor to the 3D bioprinting in medical industry in 2022.    
• By end user, the academic & research institutes segment dominated the market in 2022 and is expected to grow at a CAGR during the forecast period.   
• Region wise, North America generated the largest revenue in 2022. However, Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.